Goodwin Biotechnology has completed its largest ever round of financing with growth capital to help fund its next stage of expansion. The growth capital will be used to support Goodwin’s investments in doubling its space available for cGMP capacity as it readies for further expansion of its biopharmaceutical manufacturing, including support for commercial product manufacturing and developing various capabilities to better serve its growing customer base.
 
Goodwin is a full GMP, FDA-registered biopharmaceuticals contract development and manufacturing organization (CDMO) that offers a fully integrated Single Source Solution from cell line development, process development including bioconjugation, scale-up, cGMP contract manufacturing and aseptic fill/finish of mammalian cell-culture derived life-saving monoclonal antibodies, recombinant proteins, vaccines, and antibody drug conjugates (ADCs).
 
The investment was made by Signet Healthcare Partners, a New York-based growth equity firm specializing in healthcare investments.Nikhil Puri and Jerry Liao, investors at Signet, will join the board of directors of Goodwin.
 
“Since the early 1990s, Goodwin has served its clients in bringing their products through the clinic with our unmatched service, flexibility and quality,” said Karl Pinto, chief executive officer, Goodwin. “We are now at a point where the opportunity to grow and support our clients transcends the clinic and takes them into commercial manufacturing. Our efficient size, experience and breadth of capabilities position us very strongly to serve in particular, cutting edge new biologics products requiring small-to-mid volumes, to progress from the clinic and into the market, often within today’s shortened and abbreviated clinical pathways.”